Welcome to our dedicated page for Eloxx Pharmaceut news (Ticker: ELOX), a resource for investors and traders seeking the latest updates and insights on Eloxx Pharmaceut stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Eloxx Pharmaceut's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Eloxx Pharmaceut's position in the market.
Eloxx Pharmaceuticals (Nasdaq: ELOX) reported second quarter 2026 results and a major strengthening of its capital position following a completed underwritten public offering with $66.0 million in gross proceeds and uplisting to the Nasdaq Capital Market. Net proceeds were approximately $58.3 million, contributing to $62.0 million in cash and cash equivalents as of June 30, 2026, which the company expects will fund operations into mid‑2028 and through data readouts for exaluren in Alport syndrome and ADPKD.
Eloxx obtained FDA clearance to proceed with a Phase 2b trial of exaluren in nonsense mutation Alport syndrome, targeted to start in the third quarter of 2026, with topline 16‑week data expected by mid‑2027. Exaluren has orphan drug designation for Alport syndrome in the US and EU, and in July 2026 the European Commission granted orphan designation for exaluren in ADPKD. A Phase 2 ADPKD trial is planned for 2027. Second quarter 2026 net loss was $4.5 million, compared with $1.9 million a year earlier, driven by higher R&D and G&A expenses as clinical and corporate activities expanded.
Eloxx Pharmaceuticals (Nasdaq:ELOX) priced a public offering totaling approximately $66.0 million, consisting of 2,975,000 common shares at $11.00 and pre-funded warrants for up to 3,025,000 shares at $10.99. The common stock is expected to begin trading on the Nasdaq Capital Market on June 9, 2026, with closing targeted for June 10, 2026, subject to customary conditions.
Eloxx Pharmaceuticals (OTC: ELOX) announced key updates from its proof-of-concept trial in nonsense mutation Alport Syndrome (NMAS) patients. New protein analyses confirmed production of collagen alpha 4 and 5 in patients treated with ELX-02, with one patient showing a 34% increase in collagen a4 immunostaining intensity and a 6-fold increase in collagen a4 levels. These results justify conducting a larger clinical trial.
Additionally, the FDA has allowed continued dosing of subjects in the Phase 1 trial of ZKN-013 for treating recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa. Eloxx awaits confirmation from Almirall to proceed with the study.
Eloxx Pharmaceuticals has dosed the first two subjects in its Phase 1 clinical trial of ZKN-013, aimed at treating diseases caused by nonsense mutations like RDEB, JEB, and FAP. The company received favorable feedback from the FDA during a pre-IND meeting, paving the way for a Phase 2 trial of ELX-02 for Alport syndrome in the US. Additionally, Eloxx secured $3.2 million in financing to advance its clinical programs.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.